Genetically modified organism

Concerns

Many objections have been raised over the development of GMOs, particularly their commercialization. Many of these involve GM crops and whether food produced from them is safe and what impact growing them will have on the environment. Other concerns are the objectivity and rigor of regulatory authorities, contamination of non-genetically modified food, control of the food supply, patenting of life, and the use of intellectual property rights. Although there is a scientific consensus that currently available food derived from GM crops poses no greater risk to human health than conventional food, GM food safety is a leading issue with critics. Gene flow, impact on non-target organisms, and escape are the major environmental concerns. Countries have adopted regulatory measures to deal with these concerns. There are differences in the regulation for the release of GMOs between countries, with some of the most marked differences occurring between the US and Europe. Key issues concerning regulators include whether GM food should be labeled and the status of gene-edited organisms.

Definition

The definition of a genetically modified organism (GMO) is not clear and varies widely between countries, international bodies, and other communities. At its broadest, the definition of a GMO can include anything that has had its genes altered, including by nature. Taking a less broad view, it can encompass every organism that has had its genes altered by humans, which would include all crops and livestock. In 1993, the Encyclopedia Britannica defined genetic engineering as "any of a wide range of techniques ... among them artificial insemination, in vitro fertilization (e.g., 'test-tube' babies), sperm banks, cloning, and gene manipulation." The European Union (EU) included a similarly broad definition in early reviews, specifically mentioning GMOs being produced by "selective breeding and other means of artificial selection" These definitions were promptly adjusted with a number of exceptions added as the result of pressure from scientific and farming communities, as well as developments in science. The EU definition later excluded traditional breeding, in vitro fertilization, induction of polyploidy, mutation breeding, and cell fusion techniques that do not use recombinant nucleic acids or a genetically modified organism in the process.

Another approach was the definition provided by the Food and Agriculture Organization, the World Health Organization, and the European Commission, stating that the organisms must be altered in a way that does "not occur naturally by mating and/or natural recombination". Progress in science, such as the discovery of horizontal gene transfer being a relatively common natural phenomenon, further added to the confusion on what "occurs naturally", which led to further adjustments and exceptions. There are examples of crops that fit this definition, but are not normally considered GMOs. For example, the grain crop triticale was fully developed in a laboratory in 1930 using various techniques to alter its genome.

Genetically engineered organism (GEO) can be considered a more precise term compared to GMO when describing organisms' genomes that have been directly manipulated with biotechnology. The Cartagena Protocol on Biosafety used the synonym living modified organism (LMO) in 2000 and defined it as "any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology." Modern biotechnology is further defined as "In vitro nucleic acid techniques, including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, or fusion of cells beyond the taxonomic family."

Originally, the term GMO was not commonly used by scientists to describe genetically engineered organisms until after usage of GMO became common in popular media. The United States Department of Agriculture (USDA) considers GMOs to be plants or animals with heritable changes introduced by genetic engineering or traditional methods, while GEO specifically refers to organisms with genes introduced, eliminated, or rearranged using molecular biology, particularly recombinant DNA techniques, such as transgenesis.

The definitions focus on the process more than the product, which means there could be GMOS and non-GMOs with very similar genotypes and phenotypes. This has led scientists to label it as a scientifically meaningless category, saying that it is impossible to group all the different types of GMOs under one common definition. It has also caused issues for organic institutions and groups looking to ban GMOs. It also poses problems as new processes are developed. The current definitions came in before genome editing became popular and there is some confusion as to whether they are GMOs. The EU has adjudged that they are changing their GMO definition to include "organisms obtained by mutagenesis", but has excluded those "obtained by means of certain mutagenesis techniques, namely those which have conventionally been used in a number of applications and have a long safety record" from regulation. This refers to traditional random mutagenesis (radiation/chemical mutation breeding) and would not exclude "new techniques" (especially those that have emerged since the adoption of the GMO directive) like gene editing. In contrast the USDA has ruled that gene edited organisms are not considered GMOs.

Even greater inconsistency and confusion is associated with various "Non-GMO" or "GMO-free" labeling schemes in food marketing, where even products such as water or salt, which do not contain any organic substances and genetic material (and thus cannot be genetically modified by definition), are being labeled to create an impression of being "more healthy".

Production

Main article: Genetic engineering techniques

Creating a genetically modified organism (GMO) is a multi-step process. Genetic engineers must isolate the gene they wish to insert into the host organism. This gene can be taken from a cell or artificially synthesized. If the chosen gene or the donor organism's genome has been well studied it may already be accessible from a genetic library. The gene is then combined with other genetic elements, including a promoter and terminator region and a selectable marker.

A number of techniques are available for inserting the isolated gene into the host genome. Bacteria can be induced to take up foreign DNA, usually by exposed heat shock or electroporation. DNA is generally inserted into animal cells using microinjection, where it can be injected through the cell's nuclear envelope directly into the nucleus, or through the use of viral vectors. In plants the DNA is often inserted using Agrobacterium-mediated recombination, biolistics or electroporation.

As only a single cell is transformed with genetic material, the organism must be regenerated from that single cell. In plants this is accomplished through tissue culture. In animals it is necessary to ensure that the inserted DNA is present in the embryonic stem cells. Further testing using PCR, Southern hybridization, and DNA sequencing is conducted to confirm that an organism contains the new gene.

Traditionally the new genetic material was inserted randomly within the host genome. Gene targeting techniques, which creates double-stranded breaks and takes advantage on the cells natural homologous recombination repair systems, have been developed to target insertion to exact locations. Genome editing uses artificially engineered nucleases that create breaks at specific points. There are four families of engineered nucleases: meganucleases, zinc finger nucleases, transcription activator-like effector nucleases (TALENs), and the Cas9-guideRNA system (adapted from CRISPR). TALEN and CRISPR are the two most commonly used and each has its own advantages. TALENs have greater target specificity, while CRISPR is easier to design and more efficient.

History

Main article: History of genetic engineering

Humans have domesticated plants and animals since around 12,000 BCE, using selective breeding or artificial selection (as contrasted with natural selection). The process of selective breeding, in which organisms with desired traits (and thus with the desired genes) are used to breed the next generation and organisms lacking the trait are not bred, is a precursor to the modern concept of genetic modification. Various advancements in genetics allowed humans to directly alter the DNA and therefore genes of organisms. In 1972, Paul Berg created the first recombinant DNA molecule when he combined DNA from a monkey virus with that of the lambda virus.

Herbert Boyer and Stanley Cohen made the first genetically modified organism in 1973. They took a gene from a bacterium that provided resistance to the antibiotic kanamycin, inserted it into a plasmid and then induced other bacteria to incorporate the plasmid. The bacteria that had successfully incorporated the plasmid was then able to survive in the presence of kanamycin. Boyer and Cohen expressed other genes in bacteria. This included genes from the toad Xenopus laevis in 1974, creating the first GMO expressing a gene from an organism of a different kingdom.

In 1974, Rudolf Jaenisch created a transgenic mouse by introducing foreign DNA into its embryo, making it the world's first transgenic animal. However it took another eight years before transgenic mice were developed that passed the transgene to their offspring. Genetically modified mice were created in 1984 that carried cloned oncogenes, predisposing them to developing cancer. Mice with genes removed (termed a knockout mouse) were created in 1989. The first transgenic livestock were produced in 1985 and the first animal to synthesize transgenic proteins in their milk were mice in 1987. The mice were engineered to produce human tissue plasminogen activator, a protein involved in breaking down blood clots.

In 1983, the first genetically engineered plant was developed by Michael W. Bevan, Richard B. Flavell and Mary-Dell Chilton. They infected tobacco with Agrobacterium transformed with an antibiotic resistance gene and through tissue culture techniques were able to grow a new plant containing the resistance gene. The gene gun was invented in 1987, allowing transformation of plants not susceptible to Agrobacterium infection. In 2000, Vitamin A-enriched golden rice was the first plant developed with increased nutrient value.

In 1976, Genentech, the first genetic engineering company was founded by Herbert Boyer and Robert Swanson; a year later, the company produced a human protein (somatostatin) in E. coli. Genentech announced the production of genetically engineered human insulin in 1978. The insulin produced by bacteria, branded Humulin, was approved for release by the Food and Drug Administration in 1982. In 1988, the first human antibodies were produced in plants. In 1987, a strain of Pseudomonas syringae became the first genetically modified organism to be released into the environment when a strawberry and potato field in California were sprayed with it.

The first genetically modified crop, an antibiotic-resistant tobacco plant, was produced in 1982. China was the first country to commercialize transgenic plants, introducing a virus-resistant tobacco in 1992. In 1994, Calgene attained approval to commercially release the Flavr Savr tomato, the first genetically modified food. Also in 1994, the European Union approved tobacco engineered to be resistant to the herbicide bromoxynil, making it the first genetically engineered crop commercialized in Europe. An insect resistant Potato was approved for release in the US in 1995, and by 1996 approval had been granted to commercially grow 8 transgenic crops and one flower crop (carnation) in 6 countries plus the EU.

In 2010, scientists at the J. Craig Venter Institute announced that they had created the first synthetic bacterial genome. They named it Synthia and it was the world's first synthetic life form.

The first genetically modified animal to be commercialized was the GloFish, a Zebra fish with a fluorescent gene added that allows it to glow in the dark under ultraviolet light. It was released to the US market in 2003. In 2015, AquAdvantage salmon became the first genetically modified animal to be approved for food use. Approval is for fish raised in Panama and sold in the US. The salmon were transformed with a growth hormone-regulating gene from a Pacific Chinook salmon and a promoter from an ocean pout enabling it to grow year-round instead of only during spring and summer.

Bacteria

Main article: Genetically modified bacteria

Right: Bacteria transformed with pGLO visualized under ultraviolet light

Bacteria were the first organisms to be genetically modified in the laboratory, due to the relative ease of modifying their chromosomes. This ease made them important tools for the creation of other GMOs. Genes and other genetic information from a wide range of organisms can be added to a plasmid and inserted into bacteria for storage and modification. Bacteria are cheap, easy to grow, clonal, multiply quickly and can be stored at −80 °C almost indefinitely. Once a gene is isolated it can be stored inside the bacteria, providing an unlimited supply for research. A large number of custom plasmids make manipulating DNA extracted from bacteria relatively easy.

Their ease of use has made them great tools for scientists looking to study gene function and evolution. The simplest model organisms come from bacteria, with most of our early understanding of molecular biology coming from studying Escherichia coli. Scientists can easily manipulate and combine genes within the bacteria to create novel or disrupted proteins and observe the effect this has on various molecular systems. Researchers have combined the genes from bacteria and archaea, leading to insights on how these two diverged in the past. In the field of synthetic biology, they have been used to test various synthetic approaches, from synthesizing genomes to creating novel nucleotides.

Bacteria have been used in the production of food for a long time, and specific strains have been developed and selected for that work on an industrial scale. They can be used to produce enzymes, amino acids, flavorings, and other compounds used in food production. With the advent of genetic engineering, new genetic changes can easily be introduced into these bacteria. Most food-producing bacteria are lactic acid bacteria, and this is where the majority of research into genetically engineering food-producing bacteria has gone. The bacteria can be modified to operate more efficiently, reduce toxic byproduct production, increase output, create improved compounds, and remove unnecessary pathways. Food products from genetically modified bacteria include alpha-amylase, which converts starch to simple sugars, chymosin, which clots milk protein for cheese making, and pectinesterase, which improves fruit juice clarity. The majority are produced in the US and even though regulations are in place to allow production in Europe, as of 2015 no food products derived from bacteria are currently available there.

Genetically modified bacteria are used to produce large amounts of proteins for industrial use. The bacteria are generally grown to a large volume before the gene encoding the protein is activated. The bacteria are then harvested and the desired protein purified from them. The high cost of extraction and purification has meant that only high value products have been produced at an industrial scale. The majority of these products are human proteins for use in medicine. Many of these proteins are impossible or difficult to obtain via natural methods and they are less likely to be contaminated with pathogens, making them safer. The first medicinal use of GM bacteria was to produce the protein insulin to treat diabetes. Other medicines produced include clotting factors to treat hemophilia, human growth hormone to treat various forms of dwarfism, interferon to treat some cancers, erythropoietin for anemic patients, and tissue plasminogen activator which dissolves blood clots. Outside of medicine they have been used to produce biofuels. There is interest in developing an extracellular expression system within the bacteria to reduce costs and make the production of more products economical.

With a greater understanding of the role that the microbiome plays in human health, there is a potential to treat diseases by genetically altering the bacteria to, themselves, be therapeutic agents. Ideas include altering gut bacteria so they destroy harmful bacteria, or using bacteria to replace or increase deficient enzymes or proteins. One research focus is to modify Lactobacillus, bacteria that naturally provide some protection against HIV, with genes that will further enhance this protection. If the bacteria do not form colonies inside the patient, the person must repeatedly ingest the modified bacteria in order to get the required doses. Enabling the bacteria to form a colony could provide a more long-term solution, but could also raise safety concerns as interactions between bacteria and the human body are less well understood than with traditional drugs. There are concerns that horizontal gene transfer to other bacteria could have unknown effects. As of 2018 there are clinical trials underway testing the efficacy and safety of these treatments.

For over a century, bacteria have been used in agriculture. Crops have been inoculated with Rhizobia (and more recently Azospirillum) to increase their production or to allow them to be grown outside their original habitat. Application of Bacillus thuringiensis (Bt) and other bacteria can help protect crops from insect infestation and plant diseases. With advances in genetic engineering, these bacteria have been manipulated for increased efficiency and expanded host range. Markers have also been added to aid in tracing the spread of the bacteria. The bacteria that naturally colonize certain crops have also been modified, in some cases to express the Bt genes responsible for pest resistance. Pseudomonas strains of bacteria cause frost damage by nucleating water into ice crystals around themselves. This led to the development of ice-minus bacteria, which have the ice-forming genes removed. When applied to crops they can compete with the non-modified bacteria and confer some frost resistance.

Other uses for genetically modified bacteria include bioremediation, where the bacteria are used to convert pollutants into a less toxic form. Genetic engineering can increase the levels of the enzymes used to degrade a toxin or to make the bacteria more stable under environmental conditions. Bioart has also been created using genetically modified bacteria. In the 1980s artist Jon Davis and geneticist Dana Boyd converted the Germanic symbol for femininity (ᛉ) into binary code and then into a DNA sequence, which was then expressed in Escherichia coli. This was taken a step further in 2012, when a whole book was encoded onto DNA. Paintings have also been produced using bacteria transformed with fluorescent proteins.

Viruses

Main article: Genetically modified virus

Viruses are often modified so they can be used as vectors for inserting genetic information into other organisms. This process is called transduction and if successful the recipient of the introduced DNA becomes a GMO. Different viruses have different efficiencies and capabilities. Researchers can use this to control for various factors; including the target location, insert size, and duration of gene expression. Any dangerous sequences inherent in the virus must be removed, while those that allow the gene to be delivered effectively are retained.

While viral vectors can be used to insert DNA into almost any organism it is especially relevant for its potential in treating human disease. Although primarily still at trial stages, there has been some successes using gene therapy to replace defective genes. This is most evident in curing patients with severe combined immunodeficiency rising from adenosine deaminase deficiency (ADA-SCID), although the development of leukemia in some ADA-SCID patients along with the death of Jesse Gelsinger in a 1999 trial set back the development of this approach for many years. In 2009, another breakthrough was achieved when an eight-year-old boy with Leber's congenital amaurosis regained normal eyesight and in 2016 GlaxoSmithKline gained approval to commercialize a gene therapy treatment for ADA-SCID. As of 2018, there are a substantial number of clinical trials underway, including treatments for hemophilia, glioblastoma, chronic granulomatous disease, cystic fibrosis and various cancers.

The most common virus used for gene delivery comes from adenoviruses as they can carry up to 7.5 kb of foreign DNA and infect a relatively broad range of host cells, although they have been known to elicit immune responses in the host and only provide short term expression. Other common vectors are adeno-associated viruses, which have lower toxicity and longer-term expression, but can only carry about 4kb of DNA. Herpes simplex viruses make promising vectors, having a carrying capacity of over 30kb and providing long term expression, although they are less efficient at gene delivery than other vectors. The best vectors for long term integration of the gene into the host genome are retroviruses, but their propensity for random integration is problematic. Lentiviruses are a part of the same family as retroviruses with the advantage of infecting both dividing and non-dividing cells, whereas retroviruses only target dividing cells. Other viruses that have been used as vectors include alphaviruses, flaviviruses, measles viruses, rhabdoviruses, Newcastle disease virus, poxviruses, and picornaviruses.

Most vaccines consist of viruses that have been attenuated, disabled, weakened or killed in some way so that their virulent properties are no longer effective. Genetic engineering could theoretically be used to create viruses with the virulent genes removed. This does not affect the viruses infectivity, invokes a natural immune response and there is no chance that they will regain their virulence function, which can occur with some other vaccines. As such they are generally considered safer and more efficient than conventional vaccines, although concerns remain over non-target infection, potential side effects and horizontal gene transfer to other viruses. Another potential approach is to use vectors to create novel vaccines for diseases that have no vaccines available or the vaccines that do not work effectively, such as AIDS, malaria, and tuberculosis. The most effective vaccine against Tuberculosis, the Bacillus Calmette–Guérin (BCG) vaccine, only provides partial protection. A modified vaccine expressing a M tuberculosis antigen is able to enhance BCG protection. It has been shown to be safe to use at phase II trials, although not as effective as initially hoped. Other vector-based vaccines have already been approved and many more are being developed.

Another potential use of genetically modified viruses is to alter them so they can directly treat diseases. This can be through expression of protective proteins or by directly targeting infected cells. In 2004, researchers reported that a genetically modified virus that exploits the selfish behavior of cancer cells might offer an alternative way of killing tumours. Since then, several researchers have developed genetically modified oncolytic viruses that show promise as treatments for various types of cancer. In 2017, researchers genetically modified a virus to express spinach defensin proteins. The virus was injected into orange trees to combat citrus greening disease that had reduced orange production by 70% since 2005.

Natural viral diseases, such as myxomatosis and rabbit hemorrhagic disease, have been used to help control pest populations. Over time the surviving pests become resistant, leading researchers to look at alternative methods. Genetically modified viruses that make the target animals infertile through immunocontraception have been created in the laboratory as well as others that target the developmental stage of the animal. There are concerns with using this approach regarding virus containment and cross species infection. Sometimes the same virus can be modified for contrasting purposes. Genetic modification of the myxoma virus has been proposed to conserve European wild rabbits in the Iberian peninsula and to help regulate them in Australia. To protect the Iberian species from viral diseases, the myxoma virus was genetically modified to immunize the rabbits, while in Australia the same myxoma virus was genetically modified to lower fertility in the Australian rabbit population.

Outside of biology scientists have used a genetically modified virus to construct a lithium-ion battery and other nanostructured materials. It is possible to engineer bacteriophages to express modified proteins on their surface and join them up in specific patterns (a technique called phage display). These structures have potential uses for energy storage and generation, biosensing and tissue regeneration with some new materials currently produced including quantum dots, liquid crystals, nanorings and nanofibres. The battery was made by engineering M13 bacteriaophages so they would coat themselves in iron phosphate and then assemble themselves along a carbon nanotube. This created a highly conductive medium for use in a cathode, allowing energy to be transferred quickly. They could be constructed at lower temperatures with non-toxic chemicals, making them more environmentally friendly.

Fungi

Fungi can be used for many of the same processes as bacteria. For industrial applications, yeasts combine the bacterial advantages of being a single-celled organism that is easy to manipulate and grow with the advanced protein modifications found in eukaryotes. They can be used to produce large complex molecules for use in food, pharmaceuticals, hormones, and steroids. Yeast is important for wine production and as of 2016 two genetically modified yeasts involved in the fermentation of wine have been commercialized in the United States and Canada. One has increased malolactic fermentation efficiency, while the other prevents the production of dangerous ethyl carbamate compounds during fermentation. There have also been advances in the production of biofuel from genetically modified fungi.

Fungi, being the most common pathogens of insects, make attractive biopesticides. Unlike bacteria and viruses they have the advantage of infecting the insects by contact alone, although they are out competed in efficiency by chemical pesticides. Genetic engineering can improve virulence, usually by adding more virulent proteins,

• increasing infection rate or enhancing spore persistence. Many of the disease carrying vectors are susceptible to entomopathogenic fungi. An attractive target for biological control are mosquitos, vectors for a range of deadly diseases, including malaria, yellow fever and dengue fever. Mosquitos can evolve quickly so it becomes a balancing act of killing them before the Plasmodium they carry becomes the infectious disease, but not so fast that they become resistant to the fungi. By genetically engineering fungi like Metarhizium anisopliae and Beauveria bassiana to delay the development of mosquito infectiousness the selection pressure to evolve resistance is reduced. Another strategy is to add proteins to the fungi that block transmission of malaria or remove the Plasmodium altogether.

Agaricus bisporus the common white button mushroom, has been gene edited to resist browning, giving it a longer shelf life. The process used CRISPR to knock out a gene that encodes polyphenol oxidase. As it didn't introduce any foreign DNA into the organism it was not deemed to be regulated under existing GMO frameworks and as such is the first CRISPR-edited organism to be approved for release. This has intensified debates as to whether gene-edited organisms should be considered genetically modified organisms and how they should be regulated.

Plants

Main article: Genetically modified plant

Plants have been engineered for scientific research, to display new flower colors, deliver vaccines, and to create enhanced crops. Many plants are pluripotent, meaning that a single cell from a mature plant can be harvested and under the right conditions can develop into a new plant. This ability can be taken advantage of by genetic engineers; by selecting for cells that have been successfully transformed in an adult plant a new plant can then be grown that contains the transgene in every cell through a process known as tissue culture.

Much of the advances in the field of genetic engineering has come from experimentation with tobacco. Major advances in tissue culture and plant cellular mechanisms for a wide range of plants has originated from systems developed in tobacco. It was the first plant to be altered using genetic engineering and is considered a model organism for not only genetic engineering, but a range of other fields. As such the transgenic tools and procedures are well established making tobacco one of the easiest plants to transform. Another major model organism relevant to genetic engineering is Arabidopsis thaliana. Its small genome and short life cycle makes it easy to manipulate and it contains many homologs to important crop species. It was the first plant sequenced, has a host of online resources available and can be transformed by simply dipping a flower in a transformed Agrobacterium solution.

In research, plants are engineered to help discover the functions of certain genes. The simplest way to do this is to remove the gene and see what phenotype develops compared to the wild type form. Any differences are possibly the result of the missing gene. Unlike mutagenisis, genetic engineering allows targeted removal without disrupting other genes in the organism. Some genes are only expressed in certain tissues, so reporter genes, like GUS, can be attached to the gene of interest allowing visualization of the location. Other ways to test a gene is to alter it slightly and then return it to the plant and see if it still has the same effect on phenotype. Other strategies include attaching the gene to a strong promoter and see what happens when it is overexpressed, forcing a gene to be expressed in a different location or at different developmental stages.

Some genetically modified plants are purely ornamental. They are modified for flower color, fragrance, flower shape and plant architecture. The first genetically modified ornamentals commercialized altered color. Carnations were released in 1997, with the most popular genetically modified organism, a blue rose (actually lavender or mauve) created in 2004. The roses are sold in Japan, the United States, and Canada. Other genetically modified ornamentals include Chrysanthemum and Petunia. As well as increasing aesthetic value there are plans to develop ornamentals that use less water or are resistant to the cold, which would allow them to be grown outside their natural environments.

It has been proposed to genetically modify some plant species threatened by extinction to be resistant to invasive plants and diseases, such as the emerald ash borer in North American and the fungal disease, Ceratocystis platani, in European plane trees. The papaya ringspot virus devastated papaya trees in Hawaii in the twentieth century until transgenic papaya plants were given pathogen-derived resistance. However, genetic modification for conservation in plants remains mainly speculative. A unique concern is that a transgenic species may no longer bear enough resemblance to the original species to truly claim that the original species is being conserved. Instead, the transgenic species may be genetically different enough to be considered a new species, thus diminishing the conservation worth of genetic modification.

Crops

Main article: Genetically modified crops}}{{See also, Genetically modified food

Genetically modified crops are genetically modified plants that are used in agriculture. The first crops developed were used for animal or human food and provide resistance to certain pests, diseases, environmental conditions, spoilage or chemical treatments (e.g. resistance to a herbicide). The second generation of crops aimed to improve the quality, often by altering the nutrient profile. Third generation genetically modified crops could be used for non-food purposes, including the production of pharmaceutical agents, biofuels, and other industrially useful goods, as well as for bioremediation.

There are three main aims to agricultural advancement; increased production, improved conditions for agricultural workers and sustainability. GM crops contribute by improving harvests through reducing insect pressure, increasing nutrient value and tolerating different abiotic stresses. Despite this potential, as of 2018, the commercialized crops are limited mostly to cash crops like cotton, soybean, maize and canola and the vast majority of the introduced traits provide either herbicide tolerance or insect resistance. Soybeans accounted for half of all genetically modified crops planted in 2014. Adoption by farmers has been rapid, between 1996 and 2013, the total surface area of land cultivated with GM crops increased by a factor of 100. Geographically though the spread has been uneven, with strong growth in the Americas and parts of Asia and little in Europe and Africa. Its socioeconomic spread has been more even, with approximately 54% of worldwide GM crops grown in developing countries in 2013. Although doubts have been raised, most studies have found growing GM crops to be beneficial to farmers through decreased pesticide use as well as increased crop yield and farm profit.

The majority of GM crops have been modified to be resistant to selected herbicides, usually a glyphosate or glufosinate based one. Genetically modified crops engineered to resist herbicides are now more available than conventionally bred resistant varieties; in the USA 93% of soybeans and most of the GM maize grown is glyphosate tolerant. Most currently available genes used to engineer insect resistance come from the Bacillus thuringiensis bacterium and code for delta endotoxins. A few use the genes that encode for vegetative insecticidal proteins. The only gene commercially used to provide insect protection that does not originate from B. thuringiensis is the Cowpea trypsin inhibitor (CpTI). CpTI was first approved for use cotton in 1999 and is currently undergoing trials in rice. Less than one percent of GM crops contained other traits, which include providing virus resistance, delaying senescence and altering the plants composition.

Golden rice is the most well known GM crop that is aimed at increasing nutrient value. It has been engineered with three genes that biosynthesise beta-carotene, a precursor of vitamin A, in the edible parts of rice. It is intended to produce a fortified food to be grown and consumed in areas with a shortage of dietary vitamin A, a deficiency which each year is estimated to kill 670,000 children under the age of 5 and cause an additional 500,000 cases of irreversible childhood blindness. The original golden rice produced 1.6μg/g of the carotenoids, with further development increasing this 23 times. It gained its first approvals for use as food in 2018.

Plants and plant cells have been genetically engineered for production of biopharmaceuticals in bioreactors, a process known as pharming. Work has been done with duckweed Lemna minor, the algae Chlamydomonas reinhardtii and the moss Physcomitrella patens. Biopharmaceuticals produced include cytokines, hormones, antibodies, enzymes and vaccines, most of which are accumulated in the plant seeds. Many drugs also contain natural plant ingredients and the pathways that lead to their production have been genetically altered or transferred to other plant species to produce greater volume. Other options for bioreactors are biopolymers and biofuels. Unlike bacteria, plants can modify the proteins post-translationally, allowing them to make more complex molecules. They also pose less risk of being contaminated. Therapeutics have been cultured in transgenic carrot and tobacco cells, including a drug treatment for Gaucher's disease.

Vaccine production and storage has great potential in transgenic plants. Vaccines are expensive to produce, transport, and administer, so having a system that could produce them locally would allow greater access to poorer and developing areas. As well as purifying vaccines expressed in plants it is also possible to produce edible vaccines in plants. Edible vaccines stimulate the immune system when ingested to protect against certain diseases. Being stored in plants reduces the long-term cost as they can be disseminated without the need for cold storage, don't need to be purified, and have long term stability. Also being housed within plant cells provides some protection from the gut acids upon digestion. However the cost of developing, regulating, and containing transgenic plants is high, leading to most current plant-based vaccine development being applied to veterinary medicine, where the controls are not as strict.

Genetically modified crops have been proposed as one of the ways to reduce farming-related emissions due to higher yield, reduced use of pesticides, reduced use of tractor fuel and no tillage. According to a 2021 study, in EU alone widespread adoption of GE crops would reduce greenhouse gas emissions by 33 million tons of equivalent or 7.5% of total farming-related emissions.

Animals

Main article: Genetically modified animal

The vast majority of genetically modified animals are at the research stage with the number close to entering the market remaining small. As of 2018 only three genetically modified animals have been approved, all in the USA. A goat and a chicken have been engineered to produce medicines and a salmon has increased its own growth. Despite the differences and difficulties in modifying them, the end aims are much the same as for plants. GM animals are created for research purposes, production of industrial or therapeutic products, agricultural uses, or improving their health. There is also a market for creating genetically modified pets.

Mammals

Main article: Genetically modified mammals

The process of genetically engineering mammals is slow, tedious, and expensive. However, new technologies are making genetic modifications easier and more precise. The first transgenic mammals were produced by injecting viral DNA into embryos and then implanting the embryos in females. The embryo would develop and it would be hoped that some of the genetic material would be incorporated into the reproductive cells. Then researchers would have to wait until the animal reached breeding age and then offspring would be screened for the presence of the gene in every cell. The development of the CRISPR-Cas9 gene editing system as a cheap and fast way of directly modifying germ cells, effectively halving the amount of time needed to develop genetically modified mammals.

Mammals are the best models for human disease, making genetic engineered ones vital to the discovery and development of cures and treatments for many serious diseases. Knocking out genes responsible for human genetic disorders allows researchers to study the mechanism of the disease and to test possible cures. Genetically modified mice have been the most common mammals used in biomedical research, as they are cheap and easy to manipulate. Pigs are also a good target as they have a similar body size and anatomical features, physiology, pathophysiological response and diet. Nonhuman primates are the most similar model organisms to humans, but there is less public acceptance towards using them as research animals. In 2009, scientists announced that they had successfully transferred a gene into a primate species (marmosets) for the first time. Their first research target for these marmosets was Parkinson's disease, but they were also considering amyotrophic lateral sclerosis and Huntington's disease.

Human proteins expressed in mammals are more likely to be similar to their natural counterparts than those expressed in plants or microorganisms. Stable expression has been accomplished in sheep, pigs, rats and other animals. In 2009, the first human biological drug produced from such an animal, a goat, was approved. The drug, ATryn, is an anticoagulant which reduces the probability of blood clots during surgery or childbirth and is extracted from the goat's milk. Human alpha-1-antitrypsin is another protein that has been produced from goats and is used in treating humans with this deficiency. Another medicinal area is in creating pigs with greater capacity for human organ transplants (xenotransplantation). Pigs have been genetically modified so that their organs can no longer carry retroviruses or have modifications to reduce the chance of rejection. Chimeric pigs could carry fully human organs. The first human transplant of a genetically modified pig heart occurred in 2023, and kidney in 2024.

Livestock are modified with the intention of improving economically important traits such as growth-rate, quality of meat, milk composition, disease resistance and survival. Animals have been engineered to grow faster, be healthier and resist diseases. Modifications have also improved the wool production of sheep and udder health of cows. Goats have been genetically engineered to produce milk with strong spiderweb-like silk proteins in their milk. A GM pig called Enviropig was created with the capability of digesting plant phosphorus more efficiently than conventional pigs. They could reduce water pollution since they excrete 30 to 70% less phosphorus in manure. Dairy cows have been genetically engineered to produce milk that would be the same as human breast milk. This could potentially benefit mothers who cannot produce breast milk but want their children to have breast milk rather than formula. Researchers have also developed a genetically engineered cow that produces allergy-free milk.

Scientists have genetically engineered several organisms, including some mammals, to include green fluorescent protein (GFP), for research purposes. GFP and other similar reporting genes allow easy visualization and localization of the products of the genetic modification. Fluorescent pigs have been bred to study human organ transplants, regenerating ocular photoreceptor cells, and other topics. In 2011, green-fluorescent cats were created to help find therapies for HIV/AIDS and other diseases as feline immunodeficiency virus is related to HIV.

There have been suggestions that genetic engineering could be used to bring animals back from extinction. It involves changing the genome of a close living relative to resemble the extinct one and is currently being attempted with the passenger pigeon. Genes associated with the woolly mammoth have been added to the genome of an African Elephant, although the lead researcher says he has no intention of creating live elephants and transferring all the genes and reversing years of genetic evolution is a long way from being feasible. It is more likely that scientists could use this technology to conserve endangered animals by bringing back lost diversity or transferring evolved genetic advantages from adapted organisms to those that are struggling.

Humans

Gene therapy uses genetically modified viruses to deliver genes which can cure disease in humans. Although gene therapy is still relatively new, it has had some successes. It has been used to treat genetic disorders such as severe combined immunodeficiency, and Leber's congenital amaurosis. Treatments are also being developed for a range of other currently incurable diseases, such as cystic fibrosis, sickle cell anemia, Parkinson's disease, cancer, diabetes, heart disease and muscular dystrophy. These treatments only effect somatic cells, meaning any changes would not be inheritable. Germline gene therapy results in any change being inheritable, which has raised concerns within the scientific community.

In 2015, CRISPR was used to edit the DNA of non-viable human embryos. In November 2018, He Jiankui announced that he had edited the genomes of two human embryos, in an attempt to disable the CCR5 gene, which codes for a receptor that HIV uses to enter cells. He said that twin girls, Lulu and Nana, had been born a few weeks earlier and that they carried functional copies of CCR5 along with disabled CCR5 (mosaicism) and were still vulnerable to HIV. The work was widely condemned as unethical, dangerous, and premature.

Fish

Main article: Genetically modified fish

Genetically modified fish are used for scientific research, as pets and as a food source. Aquaculture is a growing industry, currently providing over half the consumed fish worldwide. Through genetic engineering it is possible to increase growth rates, reduce food intake, remove allergenic properties, increase cold tolerance and provide disease resistance. Fish can also be used to detect aquatic pollution or function as bioreactors.

Several groups have been developing zebrafish to detect pollution by attaching fluorescent proteins to genes activated by the presence of pollutants. The fish will then glow and can be used as environmental sensors. The GloFish is a brand of genetically modified fluorescent zebrafish with bright red, green, and orange fluorescent color. It was originally developed by one of the groups to detect pollution, but is now part of the ornamental fish trade, becoming the first genetically modified animal to become publicly available as a pet when in 2003 it was introduced for sale in the USA.

GM fish are widely used in basic research in genetics and development. Two species of fish, zebrafish and medaka, are most commonly modified because they have optically clear chorions (membranes in the egg), rapidly develop, and the one-cell embryo is easy to see and microinject with transgenic DNA. Zebrafish are model organisms for developmental processes, regeneration, genetics, behavior, disease mechanisms and toxicity testing. Their transparency allows researchers to observe developmental stages, intestinal functions and tumour growth. The generation of transgenic protocols (whole organism, cell or tissue specific, tagged with reporter genes) has increased the level of information gained by studying these fish.

GM fish have been developed with promoters driving an over-production of growth hormone for use in the aquaculture industry to increase the speed of development and potentially reduce fishing pressure on wild stocks. This has resulted in dramatic growth enhancement in several species, including salmon, trout and tilapia. AquaBounty Technologies, a biotechnology company, have produced a salmon (called AquAdvantage salmon) that can mature in half the time as wild salmon. It obtained regulatory approval in 2015, the first non-plant GMO food to be commercialized. As of August 2017, GMO salmon is being sold in Canada. Sales in the US started in May 2021.

Insects

In biological research, transgenic fruit flies (Drosophila melanogaster) are model organisms used to study the effects of genetic changes on development. Fruit flies are often preferred over other animals due to their short life cycle and low maintenance requirements. They also have a relatively simple genome compared to many vertebrates, with typically only one copy of each gene, making phenotypic analysis easy. Drosophila have been used to study genetics and inheritance, embryonic development, learning, behavior, and aging. The discovery of transposons, in particular the p-element, in Drosophila provided an early method to add transgenes to their genome, although this has been taken over by more modern gene-editing techniques.

Due to their significance to human health, scientists are looking at ways to control mosquitoes through genetic engineering. Malaria-resistant mosquitoes have been developed in the laboratory by inserting a gene that reduces the development of the malaria parasite and then use homing endonucleases to rapidly spread that gene throughout the male population (known as a gene drive). This approach has been taken further by using the gene drive to spread a lethal gene. In trials the populations of Aedes aegypti mosquitoes, the single most important carrier of dengue fever and Zika virus, were reduced by between 80% and by 90%. Another approach is to use a sterile insect technique, whereby males genetically engineered to be sterile out compete viable males, to reduce population numbers.

Other insect pests that make attractive targets are moths. Diamondback moths cause US$4 to $5 billion of damage each year worldwide. The approach is similar to the sterile technique tested on mosquitoes, where males are transformed with a gene that prevents any females born from reaching maturity. They underwent field trials in 2017. Genetically modified moths have previously been released in field trials. In this case a strain of pink bollworm that were sterilized with radiation were genetically engineered to express a red fluorescent protein making it easier for researchers to monitor them.

Silkworm, the larvae stage of Bombyx mori, is an economically important insect in sericulture. Scientists are developing strategies to enhance silk quality and quantity. There is also potential to use the silk producing machinery to make other valuable proteins. Proteins currently developed to be expressed by silkworms include; human serum albumin, human collagen α-chain, mouse monoclonal antibody and N-glycanase. Silkworms have been created that produce spider silk, a stronger but extremely difficult to harvest silk, and even novel silks.

Other

Systems have been developed to create transgenic organisms in a wide variety of other animals. Chickens have been genetically modified for a variety of purposes. This includes studying embryo development, preventing the transmission of bird flu and providing evolutionary insights using reverse engineering to recreate dinosaur-like phenotypes. A GM chicken that produces the drug Kanuma, an enzyme that treats a rare condition, in its egg passed US regulatory approval in 2015. Genetically modified frogs, in particular Xenopus laevis and Xenopus tropicalis, are used in developmental biology research. GM frogs can also be used as pollution sensors, especially for endocrine disrupting chemicals. There are proposals to use genetic engineering to control cane toads in Australia.

The nematode Caenorhabditis elegans is one of the major model organisms for researching molecular biology. RNA interference (RNAi) was discovered in C. elegans and could be induced by simply feeding them bacteria modified to express double stranded RNA. It is also relatively easy to produce stable transgenic nematodes and this along with RNAi are the major tools used in studying their genes. The most common use of transgenic nematodes has been studying gene expression and localization by attaching reporter genes. Transgenes can also be combined with RNAi techniques to rescue phenotypes, study gene function, image cell development in real time or control expression for different tissues or developmental stages. Transgenic nematodes have been used to study viruses, toxicology, diseases, and to detect environmental pollutants.

The gene responsible for albinism in sea cucumbers has been found and used to engineer white sea cucumbers, a rare delicacy. The technology also opens the way to investigate the genes responsible for some of the cucumbers more unusual traits, including hibernating in summer, eviscerating their intestines, and dissolving their bodies upon death. Flatworms have the ability to regenerate themselves from a single cell.

• Until 2017 there was no effective way to transform them, which hampered research. By using microinjection and radiation scientists have now created the first genetically modified flatworms. The bristle worm, a marine annelid, has been modified. It is of interest due to its reproductive cycle being synchronized with lunar phases, regeneration capacity and slow evolution rate. Cnidaria such as Hydra and the sea anemone Nematostella vectensis are attractive model organisms to study the evolution of immunity and certain developmental processes. Other animals that have been genetically modified include snails, geckos, turtles, crayfish, oysters, shrimp, clams, abalone and sponges.

Regulation

Main article: Regulation of genetic engineering

Genetically modified organisms are regulated by government agencies. This applies to research as well as the release of genetically modified organisms, including crops and food. The development of a regulatory framework concerning genetic engineering began in 1975, at Asilomar, California. The Asilomar meeting recommended a set of guidelines regarding the cautious use of recombinant technology and any products resulting from that technology. The Cartagena Protocol on Biosafety was adopted on 29 January 2000 and entered into force on 11 September 2003. It is an international treaty that governs the transfer, handling, and use of genetically modified organisms. One hundred and fifty-seven countries are members of the Protocol and many use it as a reference point for their own regulations.

Universities and research institutes generally have a special committee that is responsible for approving any experiments that involve genetic engineering. Many experiments also need permission from a national regulatory group or legislation. All staff must be trained in the use of GMOs and all laboratories must gain approval from their regulatory agency to work with GMOs. The legislation covering GMOs are often derived from regulations and guidelines in place for the non-GMO version of the organism, although they are more severe. There is a near-universal system for assessing the relative risks associated with GMOs and other agents to laboratory staff and the community. They are assigned to one of four risk categories based on their virulence, the severity of the disease, the mode of transmission, and the availability of preventive measures or treatments. There are four biosafety levels that a laboratory can fall into, ranging from level 1 (which is suitable for working with agents not associated with disease) to level 4 (working with life-threatening agents). Different countries use different nomenclature to describe the levels and can have different requirements for what can be done at each level.

There are differences in the regulation for the release of GMOs between countries, with some of the most marked differences occurring between the US and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety. Some nations have banned the release of GMOs or restricted their use, and others permit them with widely differing degrees of regulation. In 2016, thirty eight countries officially ban or prohibit the cultivation of GMOs and nine (Algeria, Bhutan, Kenya, Kyrgyzstan, Madagascar, Peru, Russia, Venezuela and Zimbabwe) ban their importation. Most countries that do not allow GMO cultivation do permit research using GMOs. Despite regulation, illegal releases have sometimes occurred, due to weakness of enforcement.

The European Union (EU) differentiates between approval for cultivation within the EU and approval for import and processing. While only a few GMOs have been approved for cultivation in the EU a number of GMOs have been approved for import and processing. The cultivation of GMOs has triggered a debate about the market for GMOs in Europe. Depending on the coexistence regulations, incentives for cultivation of GM crops differ. The US policy does not focus on the process as much as other countries, looks at verifiable scientific risks and uses the concept of substantial equivalence. Whether gene edited organisms should be regulated the same as genetically modified organism is debated. USA regulations sees them as separate and does not regulate them under the same conditions, while in Europe a GMO is any organism created using genetic engineering techniques.

One of the key issues concerning regulators is whether GM products should be labeled. The European Commission says that mandatory labeling and traceability are needed to allow for informed choice, avoid potential false advertising and facilitate the withdrawal of products if adverse effects on health or the environment are discovered. The American Medical Association and the American Association for the Advancement of Science say that absent scientific evidence of harm even voluntary labeling is misleading and will falsely alarm consumers. Labeling of GMO products in the marketplace is required in 64 countries. Labeling can be mandatory up to a threshold GM content level (which varies between countries) or voluntary. In the U.S., the National Bioengineered Food Disclosure Standard (Mandatory Compliance Date: January 1, 2022) requires labeling GM foods. In Canada, labeling of GM food is voluntary, while in Europe all food (including processed food) or feed which contains greater than 0.9% of approved GMOs must be labeled. In 2014, sales of products that had been labeled as non-GMO grew 30 percent to $1.1 billion.

Controversy

There is controversy over GMOs, especially with regard to their release outside laboratory environments. The dispute involves consumers, producers, biotechnology companies, governmental regulators, non-governmental organizations, and scientists. Many of these concerns involve GM crops and whether food produced from them is safe and what impact growing them will have on the environment. These controversies have led to litigation, international trade disputes, and protests, and to restrictive regulation of commercial products in some countries. Most concerns are around the health and environmental effects of GMOs. These include whether they may provoke an allergic reaction, whether the transgenes could transfer to human cells, and whether genes not approved for human consumption could outcross into the food supply.

                                                                                                                - 

• The following language and sources, per WP:GMORfC, *
• must not be altered without achieving consensus. * - --There is a scientific consensus that currently available food derived from GM crops poses no greater risk to human health than conventional food, but that each GM food needs to be tested on a case-by-case basis before introduction. Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe. The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation. -
• End of restricted section * - --

As late as the 1990s gene flow into wild populations was thought to be unlikely and rare, and if it were to occur, easily eradicated. It was thought that this would add no additional environmental costs or risks – no effects were expected other than those already caused by pesticide applications. However, in the decades since, several such examples have been observed. Gene flow between GM crops and compatible plants, along with increased use of broad-spectrum herbicides, can increase the risk of herbicide resistant weed populations. Debate over the extent and consequences of gene flow intensified in 2001 when a paper was published showing transgenes had been found in landrace maize in Mexico, the crop's center of diversity. Gene flow from GM crops to other organisms has been found to generally be lower than what would occur naturally. In order to address some of these concerns some GMOs have been developed with traits to help control their spread. To prevent the genetically modified salmon inadvertently breeding with wild salmon, all the fish raised for food are females, triploid, 99% are reproductively sterile, and raised in areas where escaped salmon could not survive. Bacteria have also been modified to depend on nutrients that cannot be found in nature, and genetic use restriction technology has been developed, though not yet marketed, that causes the second generation of GM plants to be sterile.

Other environmental and agronomic concerns include a decrease in biodiversity, an increase in secondary pests (non-targeted pests) and evolution of resistant insect pests. In the areas of China and the US with Bt crops the overall biodiversity of insects has increased and the impact of secondary pests has been minimal. The impact of Bt crops on beneficial non-target organisms became a public issue after a 1999 paper suggested they could be toxic to monarch butterflies. Follow up studies have since shown that the toxicity levels encountered in the field were not high enough to harm the larvae.

Accusations that scientists are "playing God" and other religious issues have been ascribed to the technology from the beginning. With the ability to genetically engineer humans now possible there are ethical concerns over how far this technology should go, or if it should be used at all. Much debate revolves around where the line between treatment and enhancement is and whether the modifications should be inheritable. Other concerns include contamination of the non-genetically modified food supply, the rigor of the regulatory process, consolidation of control of the food supply in companies that make and sell GMOs, exaggeration of the benefits of genetic modification, or concerns over the use of herbicides with glyphosate. Other issues raised include the patenting of life and the use of intellectual property rights.

There are large differences in consumer acceptance of GMOs, with Europeans more likely to view GM food negatively than North Americans. GMOs arrived on the scene as the public confidence in food safety, attributed to recent food scares such as Bovine spongiform encephalopathy and other scandals involving government regulation of products in Europe, was low. This along with campaigns run by various non-governmental organizations (NGO) have been very successful in blocking or limiting the use of GM crops. NGOs like the Organic Consumers Association, the Union of Concerned Scientists, Greenpeace and other groups have said that risks have not been adequately identified and managed and that there are unanswered questions regarding the potential long-term impact on human health from food derived from GMOs. They propose mandatory labeling or a moratorium on such products.

References

| And contrast:

| |

References

1. "Food, genetically modified".
2. (April 2020). "The human health benefits from GM crops". Plant Biotechnology Journal.
3. (4 October 2016). "Nature, The First Creator of GMOs".
4. Blakemore, E. (May 7, 2015). "The First GMO Is 8,000 Years Old".
5. (1993). "The new encyclopaedia Britannica". Encyclopaedia Britannica.
6. Staff [http://ec.europa.eu/agriculture/publi/gmo/gmo.pdf Economic Impacts of Genetically Modified Crops on the Agri-Food Sector; p. 42 Glossary – Term and Definitions] {{webarchive. link. (14 May 2013 The European Commission Directorate-General for Agriculture, "Genetic engineering: The manipulation of an organism's genetic endowment by introducing or eliminating specific genes through modern molecular biology techniques. A broad definition of genetic engineering also includes selective breeding and other means of artificial selection", Retrieved 5 November 2012)
7. The European Parliament and the council of the European Union. (12 March 2001). "Directive on the release of genetically modified organisms (GMOs) Directive 2001/18/EC ANNEX I A". Official Journal of the European Communities.
8. (27 August 2018). "Environmental Science – a Canadian perspective". [[Dalhousie University]].
9. "Section 2: Description and Definitions".
10. "Frequently asked questions on genetically modified foods".
11. (29 June 2010). "The EU Legislation on GMOs – An Overview".
12. (13 October 2016). "GMOs and Horizontal Gene Transfer".
13. (September 2016). "Genetically modified foods: A critical review of their promise and problems". Food Science and Human Wellness.
14. (2014). "Why we need GMO crops in agriculture". Missouri Medicine.
15. Center for Food Safety and Applied Nutrition. "Food from Genetically Engineered Plants – Consumer Info About Food from Genetically Engineered Plants".
16. Secretariat of the Convention on Biological Diversity. Montreal: 2000. The Cartagena Protocol on Biosafety to the Convention on Biological Diversity.
17. (29 February 2012). "Frequently Asked Questions (FAQs) on the Cartagena Protocol".
18. "What Is the Difference Between Genetically Modified Organisms and Genetically Engineered Organisms?".
19. "Agricultural Biotechnology Glossary {{!}} USDA".
20. (2007). "The semantics of the term 'genetically modified organism' // Genetic impact of aquaculture activities on native populations.". Genimpact Final Scientific Report (E U Contract N. RICA-CT -2005-022802).
21. (2007). "The History and Future of GMOs in Food and Agriculture". Cereal Foods World.
22. (3 November 2014). "Why the term GMO is 'scientifically meaningless'".
23. (September 2015). "The nonsensical GMO pseudo-category and a precautionary rabbit hole". Nature Biotechnology.
24. (22 August 2014). "National Organic Standards Board Materials/GMO Subcommittee Second Discussion Document on Excluded Methods Terminology".
25. "Here's Why You Should Vote Against Measure P, Even If You Hate GMOs".
26. (25 July 2018). "Gene-edited plants and animals are GM foods, EU court rules". The Guardian.
27. "New plant-breeding techniques Applicability of EU GMO rules".
28. "Organisms obtained by mutagenesis are GMOs and are, in principle, subject to the obligations laid down by the GMO Directive".
29. (1 June 2018). "Viewpoint: Non-GMO salt exploits Americans' scientific illiteracy".
30. (28 May 2018). "A sad day for our society when salt is labeled non-GMO".
31. (24 August 2015). "Non GMO salt? Water? Food companies exploit GMO free labels, misleading customers, promoting misinformation".
32. (29 May 2008). "An Introduction to Genetic Engineering". Cambridge University Press.
33. (2011). "Synthetic biology: putting synthesis into biology". Wiley Interdisciplinary Reviews: Systems Biology and Medicine.
34. (January 2010). "Personal reflections on the origins and emergence of recombinant DNA technology". Genetics.
35. (December 2016). "Impact of heat shock step on bacterial transformation efficiency". Molecular Biology Research Communications.
36. (March 2004). "DNA uptake during bacterial transformation". Nature Reviews. Microbiology.
37. National Research Council (US) Committee on Identifying and Assessing Unintended Effects of Genetically Engineered Foods on Human Health. (1 January 2004). "Methods and Mechanisms for Genetic Manipulation of Plants, Animals, and Microorganisms". National Academies Press (US).
38. (March 2003). "Agrobacterium-mediated plant transformation: the biology behind the 'gene-jockeying' tool". Microbiology and Molecular Biology Reviews.
39. (2009). "Genetically Modified Plants: Assessing Safety and Managing Risk". Academic Press.
40. (October 2005). "Validation overview of bio-analytical methods". Gene Therapy.
41. (1994). "Plant Cell and Tissue Culture". Tata McGraw-Hill Education.
42. (31 October 2002). "Genetic Engineering: Principles and Methods". Springer Science & Business Media.
43. (September 2009). "Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease". Nucleic Acids Research.
44. (January 2010). "Heritable targeted mutagenesis in maize using a designed endonuclease". The Plant Journal.
45. (May 2009). "High-frequency modification of plant genes using engineered zinc-finger nucleases". Nature.
46. (May 2009). "Precise genome modification in the crop species Zea mays using zinc-finger nucleases". Nature.
47. (October 2010). "Targeting DNA double-strand breaks with TAL effector nucleases". Genetics.
48. (January 2011). "TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain". Nucleic Acids Research.
49. (2013). "Genome-scale engineering for systems and synthetic biology". Molecular Systems Biology.
50. (2012). "Advances in Genetics Volume 80".
51. (24 April 2017). "Plant genome editing with TALEN and CRISPR". Cell & Bioscience.
52. (2009). "Hybrid: The History and Science of Plant Breeding". University of Chicago Press.
53. Clive Root. (2007). ["Domestication"]({{google books). Greenwood Publishing Groups.
54. (2012). ["Domestication of Plants in the Old World: The Origin and Spread of Plants in the Old World"]({{google books). Oxford University Press.
55. (October 1972). "Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli". Proceedings of the National Academy of Sciences of the United States of America.
56. (25 August 2008). ["Bioethics And Biosafety"]({{google books). I. K. International Pvt Ltd.
57. (January 2003). "The birth of biotechnology". Nature.
58. (May 1974). "Replication and transcription of eukaryotic DNA in Escherichia coli". Proceedings of the National Academy of Sciences of the United States of America.
59. (April 1974). "Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA". Proceedings of the National Academy of Sciences of the United States of America.
60. (2 November 2016). "'Any idiot can do it.' Genome editor CRISPR could put mutant mice in everyone's reach". Science {{!}} AAAS.
61. (December 1981). "Integration and stable germ line transmission of genes injected into mouse pronuclei". Science.
62. (November 1981). "Introduction of a rabbit beta-globin gene into the mouse germ line". Nature.
63. (September 2007). "The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer". Genes & Development.
64. (February 2003). "Cloned transgenic cattle produce milk with higher levels of beta-casein and kappa-casein". Nature Biotechnology.
65. (July 1998). "The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins". Journal of Mammary Gland Biology and Neoplasia.
66. (1987). "Production of human tissue plasminogen activator in transgenic mouse milk. 1987". Biotechnology.
67. (1983). "A chimaeric antibiotic resistance gene as a selectable marker for plant cell transformation. 1983". Nature.
68. (2011). "Challenges in Delivery of Therapeutic Genomics and Proteomics".
69. (January 1979). "Expression in Escherichia coli of chemically synthesized genes for human insulin". Proceedings of the National Academy of Sciences of the United States of America.
70. (15 November 1982). "Artificial Genes".
71. (May 2004). "Plant molecular farming: systems and products". Plant Cell Reports.
72. BBC News 14 June 2002 [https://news.bbc.co.uk/2/hi/science/nature/2045286.stm GM crops: A bitter harvest?]
73. Maugh, Thomas H. II. (9 June 1987). "Altered Bacterium Does Its Job: Frost Failed to Damage Sprayed Test Crop, Company Says". [[Los Angeles Times]].
74. (August 1983). "Expression of bacterial genes in plant cells". Proceedings of the National Academy of Sciences of the United States of America.
75. James, Clive. (1997). "Global Status of Transgenic Crops in 1997". ISAAA Briefs No. 5..
76. (2000). "The case of the FLAVR SAVR tomato". California Agriculture.
77. Debora MacKenzie. (18 June 1994). "Transgenic tobacco is European first".
78. [https://news.google.com/newspapers?id=A0YyAAAAIBAJ&sjid=jOYFAAAAIBAJ&pg=4631,1776980&dq=bacillus+thuringiensis+potato+1996+approved&hl= Genetically Altered Potato Ok'd For Crops] Lawrence Journal-World. 6 May 1995
79. (1996). "Global Review of the Field Testing and Commercialization of Transgenic Plants: 1986 to 1995". The International Service for the Acquisition of Agri-biotech Applications.
80. (July 2010). "Creation of a bacterial cell controlled by a chemically synthesized genome". Science.
81. (20 May 2010). "Craig Venter creates synthetic life form". guardian.co.uk.
82. (1 November 2012). "The current state of GMO governance: are we ready for GM animals?". Biotechnology Advances.
83. (21 November 2003). "Glowing fish to be first genetically changed pet". CNN.
84. (19 November 2015). "Genetically Engineered Salmon Approved for Consumption". [[The New York Times]].
85. (October 2010). "Risk Assessment and Mitigation of AquAdvantage Salmon". ISB News Report.
86. (March 2007). "Animal transgenesis: state of the art and applications". Journal of Applied Genetics.
87. "Rediscovering Biology – Online Textbook: Unit 13 Genetically Modified Organisms".
88. (March 2005). "A central repository for published plasmids". Science.
89. (2000). "Cells As Experimental Models". The Cell: A Molecular Approach.
90. (June 2018). "Microbe Mystery". [[Scientific American]].
91. (July 2013). "Tuning the dials of Synthetic Biology". Microbiology.
92. (7 May 2014). "Researchers Report Breakthrough in Creating Artificial Genetic Code". The New York Times.
93. (May 2014). "A semi-synthetic organism with an expanded genetic alphabet". Nature.
94. (1 January 2016). "Encyclopedia of Food and Health". Encyclopedia of Food and Health.
95. Panesar, Pamit et al. (2010) ''Enzymes in Food Processing: Fundamentals and Potential Applications'', Chapter 10, I K International Publishing House, {{ISBN. 978-93-80026-33-6
96. (3 August 2015). "Genetic Modification and Food Quality: A Down to Earth Analysis". John Wiley & Sons.
97. (2009). "Genetically Modified Organisms the Mystery Unraveled". Eloquent Books.
98. (February 2018). "Genetic engineering modification and fermentation optimization for extracellular production of recombinant proteins using Escherichia coli". Applied Microbiology and Biotechnology.
99. (January 2008). "Protein therapeutics: a summary and pharmacological classification". Nature Reviews. Drug Discovery.
100. (April 2005). "Therapeutic insulins and their large-scale manufacture". Applied Microbiology and Biotechnology.
101. (May 2008). "Recombinant clotting factors". Thrombosis and Haemostasis.
102. (July 2007). "Recombinant growth hormone for idiopathic short stature in children and adolescents". The Cochrane Database of Systematic Reviews.
103. (January 2007). "Recombinant growth hormone for children and adolescents with Turner syndrome". The Cochrane Database of Systematic Reviews.
104. Summers, Rebecca (24 April 2013). [https://www.newscientist.com/article/dn23431-bacteria-churn-out-first-ever-petrollike-biofuel.html "Bacteria churn out first ever petrol-like biofuel"]. ''New Scientist'', Retrieved 27 April 2013
105. (June 2018). "Genetically modified bacteria enlisted in fight against disease". Nature.
106. (November 2002). "Genetically modified bacteria in agriculture". Biochimie.
107. (March 2018). "Contemporary enzyme based technologies for bioremediation: A review". Journal of Environmental Management.
108. (December 2015). "Bioart". Trends in Biotechnology.
109. (September 2012). "Next-generation digital information storage in DNA". Science.
110. (December 2013). "General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination". Current Gene Therapy.
111. "Is gene therapy available to treat my disorder?". Genetics Home Reference.
112. (June 2017). "ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products". EMBO Molecular Medicine.
113. (May 2018). "Viral Vectors in Gene Therapy". Diseases.
114. (February 2011). "Gene therapy finds its niche". Nature Biotechnology.
115. (2013). "HSV as a Vector in Vaccine Development and Gene Therapy". Landes Bioscience.
116. (November 2006). "Use of genetically modified viruses and genetically engineered virus-vector vaccines: environmental effects". Journal of Toxicology and Environmental Health. Part A.
117. (March 2013). "Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial". Lancet.
118. (June 2014). "Vaccines for the 21st century". EMBO Molecular Medicine.
119. (December 2016). "Vector-based genetically modified vaccines: Exploiting Jenner's legacy". Vaccine.
120. "Genetically-modified virus explodes cancer cells".
121. "GM virus shrinks cancer tumours in humans".
122. (November 2011). "Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells". Gene Therapy.
123. Perett, Linda (30 June 2011) [http://benchmarks.cancer.gov/2011/06/measles-viruses-genetically-modified-to-treat-ovarian-cancer/ Measles viruses genetically modified to treat ovarian cancer] National Cancer Institute, Benchmarks, Retrieved 5 September 2012
124. (July 2012). "Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594". Current Pharmaceutical Biotechnology.
125. Beasley, Deena (31 August 2011) [https://www.reuters.com/article/us-cancer-virus-idUSTRE77U4NC20110831 Cancer-fighting virus shown to target tumors alone] Reuters Science, Retrieved 5 September 2012
126. (March 2006). "China approves world's first oncolytic virus therapy for cancer treatment". Journal of the National Cancer Institute.
127. (12 April 2017). "Florida's Orange Trees Are Dying, But a Weaponized Virus Could Save Them".
128. (7 August 2002). "GM virus curbs rabbits".
129. (26 February 2005). "Virus planned to counter cane toad". The Guardian.
130. "Virus could sterilise Australia's rabbits".
131. (December 2002). "First synthesize new viruses then regulate their release? The case of the wild rabbit". Molecular Ecology.
132. (September 2016). "Genetically Engineered Phages: a Review of Advances over the Last Decade". Microbiology and Molecular Biology Reviews.
133. (May 2009). "Fabricating genetically engineered high-power lithium-ion batteries using multiple virus genes". Science.
134. (2008). "Metabolically engineered yeasts: 'potential' industrial applications". Journal of Molecular Microbiology and Biotechnology.
135. (4 June 2013). "GM fungi: New way to produce cheap biofuel".
136. (December 2014). "Not all GMOs are crop plants: non-plant GMO applications in agriculture". Transgenic Research.
137. (1 January 2016). "Genetics and Molecular Biology of Entomopathogenic Fungi".
138. (April 2011). "Viability of GM fungi crucial to malaria control". Science.
139. (14 April 2016). "Gene-edited CRISPR mushroom escapes US regulation". Nature.
140. (15 April 2016). "Will Genetically 'Edited' Food Be Regulated? The Case of the Mushroom". National Public Radio.
141. (27 July 2018). "What Is a Genetically Modified Crop? A European Ruling Sows Confusion". The New York Times.
142. (2002). "Molecular Biology of the Cell". Garland Science.
143. (2004). "Tobacco (Nicotiana tabacum L.) — A Model System for Tissue Culture Interventions and Genetic Engineering". Indian Journal of Biotechnology.
144. (2007). "Genetycznie modyfikowany tytoń – szansa czy zagrozenie dla palaczy?". Przeglad Lekarski.
145. (15 June 2011). "Transgenic Horticultural Crops: Challenges and Opportunities". CRC Press.
146. (1995). "The impact of Arabidopsis research on plant biotechnology". Biotechnology Advances.
147. (October 2018). "Arabidopsis: the original plant chassis organism". Plant Cell Reports.
148. (December 1987). "GUS fusions: beta-glucuronidase as a sensitive and versatile gene fusion marker in higher plants". The EMBO Journal.
149. "Biotechnology in Ornamental Plants – Pocket K".
150. (October 2012). "Genetic modification; the development of transgenic ornamental plant varieties". Plant Biotechnology Journal.
151. (15 September 2011). "Suntory Creates Mythical Blue (Or, Um, Lavender-ish) Rose". Popular Science.
152. (11 September 2011). "Suntory to sell blue roses overseas". [[The Japan Times]].
153. (14 September 2011). "World's First 'Blue' Rose Soon Available in U.S".
154. (27 October 2009). "Green genetic engineering now conquers the ornamental plant market as well". Bioeconomy in Baden-Württemberg.
155. (1 August 2002). "The Case for Genetic Engineering of Native and Landscape Trees against Introduced Pests and Diseases". Conservation Biology.
156. (2007). "Development of genetically engineered resistant papaya for papaya ringspot virus in a timely manner: a comprehensive and successful approach".
157. (29 April 2016). "Genetically Modified Crops and Agricultural Development". Springer.
158. "Global Status of Commercialized Biotech/GM Crops: 2014 – ISAAA Brief 49-2014". ISAAA.org.
159. ISAAA 2013 Annual Report [http://www.isaaa.org/resources/publications/briefs/46/executivesummary/ Executive Summary, Global Status of Commercialized Biotech/GM Crops: 2013] ISAAA Brief 46-2013, Retrieved 6 August 2014
160. (29 October 2016). "Doubts About the Promised Bounty of Genetically Modified Crops". The New York Times.
161. (February 2013). "Economic and agronomic impact of commercialized GM crops: a meta-analysis". The Journal of Agricultural Science.
162. (10 May 2011). "A Meta Analysis on Farm-Level Costs and Benefits of GM Crops". Sustainability.
163. (3 November 2014). "A meta-analysis of the impacts of genetically modified crops". PLOS ONE.
164. (August 2013). "Pleiotropic effects of herbicide-resistance genes on crop yield: a review". Pest Management Science.
165. (September 2014). "Current state of herbicides in herbicide-resistant crops". Pest Management Science.
166. (2014). "Plant Biotechnology".
167. "SGK321". ISAAA.org.
168. (October 2008). "Is China ready for GM rice?". Nature.
169. (January 2000). "Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm". Science.
170. (21 November 2006). "'Green revolution' hero". [[The Washington Times]].
171. (January 2008). "Maternal and child undernutrition: global and regional exposures and health consequences". Lancet.
172. (1992). "Vitamin A deficiency and attributable mortality among under-5-year-olds". Bulletin of the World Health Organization.
173. (April 2005). "Improving the nutritional value of Golden Rice through increased pro-vitamin A content". Nature Biotechnology.
174. (29 May 2018). "US FDA approves GMO Golden Rice as safe to eat". Genetic Literacy Project.
175. (March 2003). "Advantages of Therapeutic Protein Production in the Aquatic Plant ''Lemna''". BioProcessing Journal.
176. (10 December 2012) [http://phys.org/news/2012-12-algae-complex-anti-cancer-drug.html "Engineering algae to make complex anti-cancer 'designer' drug"]. ''PhysOrg'', Retrieved 15 April 2013
177. (April 2011). "Production of biologically active recombinant human factor H in Physcomitrella". Plant Biotechnology Journal.
178. (May 2005). "Enhanced recovery of a secreted recombinant human growth factor using stabilizing additives and by co-expression of human serum albumin in the moss Physcomitrella patens". Plant Biotechnology Journal.
179. (6 December 2012). "Plant Biotechnology: New Products and Applications". Springer Science & Business Media.
180. (June 2010). "Tailoring plant metabolism for the production of novel polymers and platform chemicals". Current Opinion in Plant Biology.
181. (June 2009). "Closed photo-bioreactors as tools for biofuel production". Current Opinion in Biotechnology.
182. "UNL's AgBiosafety for Educators".
183. "ProCellEx® Platform".
184. link. (29 May 2013)
185. (May 2017). "Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines?". Vaccines.
186. (10 February 2021). "The climate benefits of yield increases in genetically engineered crops".
187. (May 2013). "Genetically modified farm animals and fish in agriculture: A review.". Livestock Science.
188. "The Superpowers of Genetically Modified Pigs".
189. Rudinko, Larisa (20). Guidance for industry. USA: Center for veterinary medicine [https://web.archive.org/web/20090709170807/http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM113903.pdf Link.]
190. Murray, Joo (20). [http://www.brainwaving.com/2010/07/28/genetically-modified-animals Genetically modified animals] {{Webarchive. link. (13 October 2019 . Canada: Brainwaving)
191. (23 May 2018). "How CRISPR is Spreading Through the Animal Kingdom".
192. (January 2018). "Genetically engineered pigs as models for human disease". Disease Models & Mechanisms.
193. (February 2018). "Genetic engineering in nonhuman primates for human disease modeling". Journal of Human Genetics.
194. (May 2009). "Generation of transgenic non-human primates with germline transmission". Nature.
195. (May 2009). "Developmental biology: Transgenic primate offspring". Nature.
196. (May 2009). "Marmoset model takes centre stage". Nature.
197. Britt Erickson, 10 February 2009, for ''Chemical & Engineering News''. [https://archive.today/20130112055323/http://pubs.acs.org/cen/news/87/i07/8707notw5.html FDA Approves Drug From Transgenic Goat Milk] Accessed 6 October 2012
198. (May 2005). "Antibody response to aerosolized transgenic human alpha1-antitrypsin". The New England Journal of Medicine.
199. (15 October 2015). "Editing of Pig DNA May Lead to More Organs for People l". The New York Times.
200. (August 2013). "Transgenic pigs designed to express human α-galactosidase to avoid humoral xenograft rejection". Journal of Applied Genetics.
201. (30 April 2014). "Pig Heart Transplants For Humans Could Be on Their Way".
202. (January 2017). "Interspecies Chimerism with Mammalian Pluripotent Stem Cells". Cell.
203. (2023-11-01). "Man who received the second pig heart transplant dies, hospital says".
204. (21 March 2024). "Surgeons Transplant Pig Kidney Into a Patient, a Medical Milestone". New York Times.
205. (21 March 2024). "Pig kidney transplanted into living person for first time". CNN.
206. (April 2006). "Generation of cloned transgenic pigs rich in omega-3 fatty acids". Nature Biotechnology.
207. (24 June 2018). "Genetically modified animals". The Guardian.
208. (2010). "Scientist bred goats that produce spider silk". Phys.org.
209. (2010). "Enviropig". University of Guelph.
210. (22 June 2012). "Genetically engineered pigs killed after funding ends". Postmedia News.
211. "Enviropig – Environmental Benefits". University of Guelph.
212. (2011). "Genetically modified cows produce 'human' milk".
213. (14 April 2010). "Genetically modified cows producing human milk". Classical Medicine Journal.
214. (11 June 2011). "Scientists create cow that produces 'human' milk". [[The Daily Telegraph]].
215. (October 2012). "Targeted microRNA expression in dairy cattle directs production of β-lactoglobulin-free, high-casein milk". Proceedings of the National Academy of Sciences of the United States of America.
216. "Green fluorescent protein takes Nobel prize". Lewis Brindley.
217. (2008). "Genetically modified pigs for medicine and agriculture". Biotechnology and Genetic Engineering Reviews.
218. (September 2011). "Antiviral restriction factor transgenesis in the domestic cat". Nature Methods.
219. Staff. (3 April 2012). "Biology of HIV". National Institute of Allergy and Infectious Diseases.
220. "Ancient DNA Could Return Passenger Pigeons to the Sky".
221. "Can we grow woolly mammoths in the lab? George Church hopes so".
222. (19 February 2017). "How mammoth cloning became fake news".
223. (November 2015). "Mammoth 2.0: will genome engineering resurrect extinct species?". Genome Biology.
224. (October 2004). "Gene therapy in clinical medicine". Postgraduate Medical Journal.
225. (June 2007). "Gene therapy for severe combined immunodeficiency: are we there yet?". The Journal of Clinical Investigation.
226. (6 November 2012). "Gene therapy arrives in Europe". The Scientist.
227. (October 2006). "Gene therapy for cystic fibrosis lung disease: current status and future perspectives". Current Opinion in Molecular Therapeutics.
228. (July 2003). "Gene therapy for the hemoglobin disorders". Current Hematology Reports.
229. (April 2011). "AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomized trial". The Lancet. Neurology.
230. Gallaher, James (17 March 2011). [https://www.bbc.co.uk/news/health-12758230 "Gene therapy 'treats' Parkinson's disease"]. BBC News Health. Retrieved 24 April 2011
231. (12 February 2013). "Genetically Engineered Virus Fights Liver Cancer". United Academics.
232. (11 August 2011). "Treatment for Leukemia Is Showing Early Promise". The New York Times.
233. (26 March 2013). "Gene therapy cures leukaemia in eight days". New Scientist.
234. (13 February 2013). "Gene therapy cures diabetic dogs". New Scientist.
235. (30 April 2013). "New gene therapy trial gives hope to people with heart failure". British Heart Foundation.
236. (December 2006). "Gene therapy progress and prospects: Duchenne muscular dystrophy". Gene Therapy.
237. (5 August 2001). "1990 The Declaration of Inuyama".
238. (October 2012). "Human germline genetic modification: scientific and bioethical perspectives". Archives of Medical Research.
239. (23 April 2015). "Chinese Scientists Edit Genes of Human Embryos, Raising Concerns". The New York Times.
240. (May 2015). "CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes". Protein & Cell.
241. (28 November 2018). "Amid uproar, Chinese scientist defends creating gene-edited babies – STAT". STAT.
242. (24 July 2014). "Analyzing cold tolerance mechanism in transgenic zebrafish (Danio rerio)". PLOS ONE.
243. "Half of Fish Consumed Globally Is Now Raised on Farms, Study Finds".
244. (November 2017). "Progress and biotechnological prospects in fish transgenesis". Biotechnology Advances.
245. (January 2002). "Use of reporter genes and vertebrate DNA motifs in transgenic zebrafish as sentinels for assessing aquatic pollution". Environmental Health Perspectives.
246. (August 2001). "Green fluorescent protein (GFP) as a marker of aryl hydrocarbon receptor (AhR) function in developing zebrafish (Danio rerio)". Environmental Health Perspectives.
247. (June 2004). "Glofish, the first GM animal commercialized: profits amid controversy.". ISB News Report.
248. (2004). "Fish Development and Genetics". World Scientific, Inc..
249. (2018). "Zebrafish: Development of a Vertebrate Model Organism". Current Protocols in Essential Laboratory Techniques.
250. (September 2017). "Innovative Disease Model: Zebrafish as an In Vivo Platform for Intestinal Disorder and Tumors". Biomedicines.
251. (March 2015). "Zebrafish: a new companion for translational research in oncology". Clinical Cancer Research.
252. (April 2008). "Generation and characterization of transgenic zebrafish lines using different ubiquitous promoters". Transgenic Research.
253. (1992). "Growth Enhancement in Transgenic Atlantic Salmon by the Use of an 'All Fish' Chimeric Growth Hormone Gene Construct". Nature Biotechnology.
254. (February 2001). "Growth of domesticated transgenic fish". Nature.
255. (2001). "Growth and nutritional trials on transgenic Nile tilapia containing an exogenous fish growth hormone gene". Journal of Fish Biology.
256. (21 December 2012). "Engineered Fish Moves a Step Closer to Approval". The New York Times.
257. (19 November 2015). "FDA Has Determined That the AquAdvantage Salmon is as Safe to Eat as Non-GE Salmon".
258. "First Genetically Engineered Salmon Sold in Canada". Scientific American.
259. Smith, Casey. (21 May 2021). "Genetically modified salmon head to US dinner plates".
260. (September 2008). "Genetic modifiers of MeCP2 function in Drosophila". PLOS Genetics.
261. "Online Education Kit: 1981–82: First Transgenic Mice and Fruit Flies".
262. (2017). "Site-Specific Recombinases".
263. (1 May 2011). "Drosophila – a versatile model in biology & medicine". Materials Today.
264. (May 2017). "Genome editing in Drosophila melanogaster: from basic genome engineering to the multipurpose CRISPR-Cas9 system". Science China Life Sciences.
265. (July 2010). "Activation of Akt signaling reduces the prevalence and intensity of malaria parasite infection and lifespan in Anopheles stephensi mosquitoes". PLOS Pathogens.
266. (20 April 2011). "GM mosquitoes offer malaria hope". BBC News, Health.
267. (May 2011). "A synthetic homing endonuclease-based gene drive system in the human malaria mosquito". Nature.
268. (March 2011). "Genetic elimination of dengue vector mosquitoes". Proceedings of the National Academy of Sciences of the United States of America.
269. (6 February 2016). "Releasing millions of GM mosquitoes 'could solve zika crisis'". The Telegraph.
270. (October 2011). "Field performance of engineered male mosquitoes". Nature Biotechnology.
271. Staff (March 2011) [https://web.archive.org/web/20111110150441/http://www.oxitec.com/wp-content/uploads/2011/03/OXITEC-Newsletter-March-11-Final.pdf "Cayman demonstrates RIDL potential"]. ''Oxitec Newsletter'', March 2011. Retrieved 20 September 2011
272. (August 2003). "The first releases of transgenic mosquitoes: an argument for the sterile insect technique". Trends in Parasitology.
273. (8 September 2017). "Genetically Modified Moths Come to New York".
274. (10 May 2017). "After Mosquitos, Moths Are the Next Target For Genetic Engineering".
275. (January 2017). "Mass Releases of Genetically Modified Insects in Area-Wide Pest Control Programs and Their Impact on Organic Farmers". Sustainability.
276. (13 September 2011). "Field performance of a genetically engineered strain of pink bollworm". PLOS ONE.
277. (July 2015). "Advanced technologies for genetically manipulating the silkworm Bombyx mori, a model Lepidopteran insect". Proceedings. Biological Sciences.
278. (April 2011). "Transgenic silkworms that weave recombinant proteins into silk cocoons". Biotechnology Letters.
279. (August 2018). "Bombyx mori". Proceedings of the National Academy of Sciences of the United States of America.
280. "GM worms make a super-silk completely unknown in nature".
281. "Poultry scientists develop transgenic chicken to aid study of embryo development".
282. "Genetically modified chickens that don't transmit bird flu developed; Breakthrough could prevent future bird flu epidemics".
283. (March 2016). "Molecular development of fibular reduction in birds and its evolution from dinosaurs". Evolution; International Journal of Organic Evolution.
284. (9 December 2015). "US government approves transgenic chicken". Nature.
285. (August 2007). "An in vivo multiwell-based fluorescent screen for monitoring vertebrate thyroid hormone disruption". Environmental Science & Technology.
286. (28 July 2014). "Removing Threat from Invasive Species with Genetic Engineering?".
287. (17 November 2017). "Cane toads to get the Crispr treatment".
288. "History of research on ''C. elegans'' and other free-living nematodes as model organisms".
289. (2 October 2006). "RNAi scoops medical Nobel". Nature News.
290. (January 2015). "RNA Interference in ''Caenorhabditis elegans''". Current Protocols in Molecular Biology.
291. (2011). "Transgenesis in ''C. elegans''".
292. (November 2014). "The nematode ''Caenorhabditis elegans'' as a model to study viruses". Archives of Virology.
293. (2016). "Reviews of Environmental Contamination and Toxicology Volume 237". Reviews of Environmental Contamination and Toxicology.
294. (2018). "Polyglutamine Disorders".
295. (December 2017). "Genetic and Pharmacological Discovery for Alzheimer's Disease Using ''Caenorhabditis elegans''". ACS Chemical Neuroscience.
296. (2002). "Biotechnology for the Environment: Strategy and Fundamentals". Springer, Dordrecht.
297. (5 August 2015). "More valuable than gold, but not for long: genetically-modified sea cucumbers headed to China's dinner tables".
298. (December 2017). "Efficient transgenesis and annotated genome sequence of the regenerative flatworm model Macrostomum lignano". Nature Communications.
299. (May 2014). "Genetic and genomic tools for the marine annelid Platynereis dumerilii". Genetics.
300. (April 2006). "Transgenic Hydra allow in vivo tracking of individual stem cells during morphogenesis". Proceedings of the National Academy of Sciences of the United States of America.
301. (February 2015). "CRISPR/Cas9-mediated genome modification in the mollusc, Crepidula fornicata". Genesis.
302. (24 February 2015). "Genetic manipulation of reptilian embryos: toward an understanding of cortical development and evolution". Frontiers in Neuroscience.
303. (2007). "Biotechnology in Aquaculture: Transgenics and Polyploidy". Comprehensive Reviews in Food Science and Food Safety.
304. (November 2010). "MicroRNA sponges: progress and possibilities". RNA.
305. (June 1975). "Summary statement of the Asilomar conference on recombinant DNA molecules". Proceedings of the National Academy of Sciences of the United States of America.
306. (18 May 2021). "About the Protocol". The Biosafety Clearing-House (BCH).
307. (2007). "The Cartagena Protocol on biosafety: Precautionary priority in biotech crop approvals and containment of commodities shipments, 2007". Colorado Journal of International Environmental Law and Policy.
308. "Implications of import regulations and information requirements under the Cartagena Protocol on biosafety for GM commodities in Kenya.". AgBioForum.
309. (31 May 2016). "Biotechnology: An Illustrated Primer". John Wiley & Sons.
310. (July 2008). "Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures". Clinical Microbiology Reviews.
311. (July 1999). "Worlds apart? The reception of genetically modified foods in Europe and the U.S". Science.
312. (11 December 2013). "The History and Future of GM Potatoes".
313. (February 2013). "FDA and Regulation of GMOs". American Bar Association.
314. (7 February 2016). "Where are GMOs grown and banned?".
315. (2016). "The coexistence of genetically modified, organic and conventional foods". Springer.
316. "EU Policy for Agriculture, Food and Rural Areas". Wageningen Academic Publishers.
317. (2016). "The Coexistence of Genetically Modified, Organic and Conventional Foods". Springer Science.
318. (July 2011). "Genetically modified food and global welfare". Emerald Group Publishing.
319. Emily Marden, Risk and Regulation: U.S. Regulatory Policy on Genetically Modified Food and Agriculture, 44 B.C.L. Rev. 733 (2003)[http://lawdigitalcommons.bc.edu/cgi/viewcontent.cgi?article=2236&context=bclr]
320. (May 2018). "A CRISPR definition of genetic modification". Nature Plants.
321. (2003). "Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 On Genetically Modified Food And Feed". Official Journal of the European Union L 268/3 (21).
322. (2003). "Regulation (EC) No 1830/2003 of the European Parliament and of the Council of 22 September 2003 concerning the traceability and labeling of genetically modified organisms and the traceability of food and feed products produced from genetically modified organisms and amending Directive 2001/18/EC". The European Parliament and the Council of the European Union.
323. (2012). "Report 2 of the Council on Science and Public Health: Labeling of Bioengineered Foods". American Medical Association.
324. American Association for the Advancement of Science (AAAS), Board of Directors (2012). [http://www.aaas.org/sites/default/files/AAAS_GM_statement.pdf Statement by the AAAS Board of Directors On Labeling of Genetically Modified Foods], and associated [http://www.aaas.org/news/releases/2012/1025gm_statement.shtml Press release: Legally Mandating GM Food Labels Could Mislead and Falsely Alarm Consumers] {{Webarchive. link. (4 November 2013)
325. (27 April 2014). "How GMO labeling came to pass in Vermont". Burlington Free Press.
326. (21 December 2018). "National Bioengineered Food Disclosure Standard".
327. "The Regulation of Genetically Modified Foods".
328. (2010). "GM plants: Science, politics and EC regulations". Plant Science.
329. Smithsonian. (2015). "Some Brands Are Labeling Products 'GMO-free' Even if They Don't Have Genes".
330. (1 March 2002). "Regulation of biotechnology: will we ever 'freely' trade GMOs?". European Review of Agricultural Economics.
331. (6–10 September 1993). "The impact of developing herbicide resistant crop plants".
332. (May 2013). "Case studies: A hard look at GM crops". Nature.
333. (21 January 2017). "Herbicide resistance and biodiversity: agronomic and environmental aspects of genetically modified herbicide-resistant plants". Environmental Sciences Europe.
334. (November 2008). "Modified genes spread to local maize". Nature.
335. (November 2017). "Transgene flow in Mexican maize revisited: Socio-biological analysis across two contrasting farmer communities and seed management systems". Ecology and Evolution.
336. (20 September 2008). "Risks from GMOs due to horizontal gene transfer". Environmental Biosafety Research.
337. (2012). "FDA: Genetically engineered fish would not harm nature". USA Today.
338. Center for Veterinary Medicine. "Animals with Intentional Genomic Alterations – AquAdvantage Salmon Fact Sheet".
339. (9 November 2015). "Containing Genetically Modified Bacteria". National Institutes of Health (NIH).
340. (October 2014). "Genetic use restriction technologies: a review". Plant Biotechnology Journal.
341. (1 January 2011). "Impact of GM crops on biodiversity". GM Crops.
342. (June 2013). "Insect resistance to Bt crops: lessons from the first billion acres". Nature Biotechnology.
343. (13 May 2010). "GM crop use makes minor pests major problem". Nature News.
344. "Report in Brief – Genetically Engineered Crops". National Academy of Sciences.
345. (September 2009). "GM crops: Battlefield". Nature.
346. (December 2009). "Playing God? Synthetic biology as a theological and ethical challenge". Systems and Synthetic Biology.
347. (2015). "Genetically engineering humans: a step too far?".
348. "Human genome editing shouldn't be used for enhancement – yet".
349. [[Chartered Institute of Environmental Health]] (2006) [http://www.cieh.org/uploadedFiles/Core/Policy/CIEH_consultation_responses/Response_GM_final.pdf "Proposals for managing the coexistence of GM, conventional and organic crops Response to the Department for Environment, Food and Rural Affairs consultation paper"] {{Webarchive. link. (25 May 2017 . October 2006)
350. (2015). "GMOs and organic agriculture: Six lessons from Australia". Agriculture & Forestry.
351. [[American Medical Association]] (2012). [http://www.ama-assn.org/resources/doc/csaph/a12-csaph2-bioengineeredfoods.pdf "Report 2 of the Council on Science and Public Health: Labeling of Bioengineered Foods"] {{Webarchive. link. (7 September 2012 . "To better detect potential harms of bioengineered foods, the Council believes that pre-market safety assessment should shift from a voluntary notification process to a mandatory requirement." p. 7)
352. (17 May 2016). "GMOs Are Safe, But Don't Always Deliver on Promises, Top Scientists Say".
353. (August 2015). "GMOs, Herbicides, and Public Health". The New England Journal of Medicine.
354. (October 2000). "Patenting life: genetically altered mice an invention, court declares". CMAJ.
355. (10 August 2015). "The Patent Landscape of Genetically Modified Organisms". Science in the News.
356. (July 2015). "Public Acceptance of Plant Biotechnology and GM Crops". Viruses.
357. (20 January 2017). "From Mad Cows to GMOs: The Side Effects of Modernization". European Journal of Risk Regulation.
358. (July 2014). "A dubious success: the NGO campaign against GMOs". GM Crops & Food.
359. (8 July 2013). "The genetically modified food debate: Where do we begin?". Grist.
360. (22 August 2014). "On Double Standards and the Union of Concerned Scientists". Discover.
361. (24 November 2025). "Risk and Regulation: U.S. Regulatory Policy on Genetically Modified Food and Agriculture". 44 B.C.L. Rev. 733 (2003)..
362. (14 April 2016). "Science, Risk, and Policy". Routledge.
363. (March 2004). "Genetically modified food and health: A second interim statement". [[British Medical Association]] Board of Science and Education.
364. (2007). "Genetically Modified Foods". Public Health Association of Australia.
365. [[Canadian Association of Physicians for the Environment]] (2013) [http://cape.ca/capes-position-statement-on-gmos/ "Statement on Genetically Modified Organisms in the Environment and the Marketplace"]. {{Webarchive. link. (26 March 2014. October 2013)
366. Irish Doctors' Environmental Association [http://ideaireland.org/library/idea-position-on-genetically-modified-foods/ "IDEA Position on Genetically Modified Foods"]. {{webarchive. link. (26 March 2014. Retrieved 25 March 2014.)
367. PR Newswire [http://www.prnewswire.co.uk/news-releases/genetically-modified-maize-doctors-chamber-warns-of-unpredictable-results-to-humans-231410601.html "Genetically Modified Maize: Doctors' Chamber Warns of 'Unpredictable Results' to Humans"]. 11 November 2013
368. (2013). "An overview of the last 10 years of genetically engineered crop safety research". Critical Reviews in Biotechnology.
369. "State of Food and Agriculture 2003–2004. Agricultural Biotechnology: Meeting the Needs of the Poor. Health and environmental impacts of transgenic crops". Food and Agriculture Organization of the United Nations.
370. Ronald, Pamela. (1 May 2011). "Plant Genetics, Sustainable Agriculture and Global Food Security". Genetics.
371. Pinholster, Ginger. (20 October 2012). "Statement by the AAAS Board of Directors on Labeling of Genetically Modified Foods". American Association for the Advancement of Science.
372. (2010). "A decade of EU-funded GMO research (2001–2010)". Publications Office of the European Union.
373. (January 2001). "AMA Report on Genetically Modified Crops and Foods (online summary)". American Medical Association.
374. (30 June 2015). "Restrictions on Genetically Modified Organisms: United States. Public and Scholarly Opinion". Library of Congress.
375. (2016). "Genetically Engineered Crops: Experiences and Prospects". The National Academies of Sciences, Engineering, and Medicine.
376. "Frequently asked questions on genetically modified foods". World Health Organization.
377. Haslberger, Alexander G.. (2003). "Codex guidelines for GM foods include the analysis of unintended effects". Nature Biotechnology.
378. (March 2004). "Genetically modified foods and health: a second interim statement". British Medical Association.
379. (29 January 2015). "Public and Scientists' Views on Science and Society". Pew Research Center.
380. Marris, Claire. (2001). "Public views on GMOs: deconstructing the myths". EMBO Reports.
381. Final Report of the PABE research project. (December 2001). "Public Perceptions of Agricultural Biotechnologies in Europe". Commission of European Communities.
382. (2016). "Evidence for Absolute Moral Opposition to Genetically Modified Food in the United States". Perspectives on Psychological Science.
383. (9 June 2015). "Restrictions on Genetically Modified Organisms". Library of Congress.
384. Bashshur, Ramona. (February 2013). "FDA and Regulation of GMOs". American Bar Association.
385. Sifferlin, Alexandra. (3 October 2015). "Over Half of E.U. Countries Are Opting Out of GMOs".
386. (5 April 2001). "The Regulation of GMOs in Europe and the United States: A Case-Study of Contemporary European Regulatory Politics". Council on Foreign Relations.